US 11,746,323 B2
PDX1 positive foregut endoderm cells and methods of production
Kevin Allen D'Amour, San Diego, CA (US); Alan D. Agulnick, San Diego, CA (US); Susan Eliazer, Moraga, CA (US); and Emmanuel E. Baetge, Encinitas, CA (US)
Assigned to ViaCyte, Inc., San Diego, CA (US)
Filed by ViaCyte, Inc., San Diego, CA (US)
Filed on Sep. 25, 2019, as Appl. No. 16/583,135.
Application 16/583,135 is a continuation of application No. 16/177,235, filed on Oct. 31, 2018, granted, now 10,465,162.
Application 16/177,235 is a continuation of application No. 14/947,999, filed on Nov. 20, 2015, abandoned.
Application 14/947,999 is a continuation of application No. 14/146,510, filed on Jan. 2, 2014, granted, now 9,222,069, issued on Dec. 29, 2015.
Application 14/146,510 is a continuation of application No. 11/587,735, granted, now 8,647,873, issued on Feb. 11, 2014, previously published as PCT/US2005/014239, filed on Apr. 26, 2005.
Application 11/587,735 is a continuation in part of application No. 11/021,618, filed on Dec. 23, 2004, granted, now 7,510,876, issued on Mar. 31, 2009.
Claims priority of provisional application 60/587,942, filed on Jul. 14, 2004.
Claims priority of provisional application 60/586,566, filed on Jul. 9, 2004.
Claims priority of provisional application 60/566,293, filed on Apr. 27, 2004.
Prior Publication US 2020/0017824 A1, Jan. 16, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/073 (2010.01); C12N 5/0735 (2010.01)
CPC C12N 5/0603 (2013.01) [C12N 5/0606 (2013.01); C12N 2501/115 (2013.01); C12N 2501/119 (2013.01); C12N 2501/15 (2013.01); C12N 2501/155 (2013.01); C12N 2501/16 (2013.01); C12N 2501/385 (2013.01); C12N 2501/415 (2013.01); C12N 2502/13 (2013.01); C12N 2506/02 (2013.01)] 8 Claims
 
1. An in vitro cell culture comprising:
human pancreatic and duodenal homeobox 1 (PDX1)-negative definitive endoderm cells;
a medium comprising an effective amount of B27, a retinoid and a fibroblast growth factor (FGF), to differentiate the PDX1-negative definitive endoderm cells to PDX1-positive foregut endoderm cells; and
PDX1-positive foregut endoderm cells,
such that the amount of PDX1 expressed by the PDX1-positive foregut endoderm cells is increased in the in vitro cell culture as compared to a second in vitro cell culture comprising human PDX1-negative definitive endoderm cells, PDX1-positive foregut endoderm cells, and the medium without B27.